18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that topical bortezomib increased cell proliferation in hair follicles and sebaceous glands in mice and may activate hair keratin gene expression through GATA-3 transcription factors.
January 2016 in “대한피부과학회지” This case report describes two patients experiencing a bortezomib-induced skin eruption as multiple plaques on the trunk, with the lesions resolving spontaneously in about a week.
474 citations
,
January 2012 in “Chemistry & biology” This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.